CA2910666A1 - Cs1-specific chimeric antigen receptor engineered immune effector cells - Google Patents

Cs1-specific chimeric antigen receptor engineered immune effector cells Download PDF

Info

Publication number
CA2910666A1
CA2910666A1 CA2910666A CA2910666A CA2910666A1 CA 2910666 A1 CA2910666 A1 CA 2910666A1 CA 2910666 A CA2910666 A CA 2910666A CA 2910666 A CA2910666 A CA 2910666A CA 2910666 A1 CA2910666 A1 CA 2910666A1
Authority
CA
Canada
Prior art keywords
cells
car
cell
domain
transduced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2910666A
Other languages
English (en)
French (fr)
Other versions
CA2910666C (en
Inventor
Jianhua Yu
Craig HOFMEISTER
Jianhong CHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of CA2910666A1 publication Critical patent/CA2910666A1/en
Application granted granted Critical
Publication of CA2910666C publication Critical patent/CA2910666C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
CA2910666A 2013-05-03 2014-05-02 Cs1-specific chimeric antigen receptor engineered immune effector cells Active CA2910666C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361819141P 2013-05-03 2013-05-03
US61/819,141 2013-05-03
US201361876492P 2013-09-11 2013-09-11
US61/876,492 2013-09-11
PCT/US2014/036684 WO2014179759A1 (en) 2013-05-03 2014-05-02 Cs1-specific chimeric antigen receptor engineered immune effector cells

Publications (2)

Publication Number Publication Date
CA2910666A1 true CA2910666A1 (en) 2014-11-06
CA2910666C CA2910666C (en) 2025-10-07

Family

ID=

Also Published As

Publication number Publication date
JP2016524598A (ja) 2016-08-18
EP3663320A1 (en) 2020-06-10
US20200002418A1 (en) 2020-01-02
JP7221338B2 (ja) 2023-02-13
CN115028735A (zh) 2022-09-09
CN105377897A (zh) 2016-03-02
EP2992020A1 (en) 2016-03-09
WO2014179759A1 (en) 2014-11-06
EP2992020A4 (en) 2016-12-28
DK2992020T3 (da) 2020-02-10
US10358494B2 (en) 2019-07-23
BR112015027567B1 (pt) 2024-02-20
BR112015027567A2 (pt) 2017-12-05
KR102098985B1 (ko) 2020-04-09
AU2019203823A1 (en) 2019-06-20
HK1218925A1 (en) 2017-03-17
US20160075784A1 (en) 2016-03-17
AU2014259675A1 (en) 2015-11-12
JP2019146579A (ja) 2019-09-05
US11845794B2 (en) 2023-12-19
AU2014259675B2 (en) 2019-05-02
JP2021177771A (ja) 2021-11-18
US10227409B2 (en) 2019-03-12
PT2992020T (pt) 2020-02-28
AU2019203823B2 (en) 2021-05-13
MX2015015182A (es) 2016-05-05
PL2992020T3 (pl) 2020-06-01
US20170320941A1 (en) 2017-11-09
ES2777940T3 (es) 2020-08-06
MX370173B (es) 2019-12-04
IL242315B (en) 2020-07-30
JP6856188B2 (ja) 2021-04-07
KR20160003071A (ko) 2016-01-08
HUE048312T2 (hu) 2020-07-28
EP2992020B1 (en) 2020-01-15

Similar Documents

Publication Publication Date Title
US11845794B2 (en) CS1-specific chimeric antigen receptor engineered immune effector cells
US20230303653A1 (en) Compositions and methods of chimeric autoantibody receptor t cells
CN110177803A (zh) 用于使用融合蛋白进行tcr重新编程的组合物和方法
CA2910666C (en) Cs1-specific chimeric antigen receptor engineered immune effector cells
HK1218925B (en) Cs1-specific chimeric antigen receptor engineered immune effector cells
HK40074993A (en) Compositions and methods of chimeric autoantibody receptor t cells
HK40063360A (en) Compositions and methods of chimeric autoantibody receptor t cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190416

EEER Examination request

Effective date: 20190416

EEER Examination request

Effective date: 20190416

EEER Examination request

Effective date: 20190416

EEER Examination request

Effective date: 20190416

EEER Examination request

Effective date: 20190416

EEER Examination request

Effective date: 20190416

EEER Examination request

Effective date: 20190416